Dr Dennis Garrett Gruwell, MD | |
Dow Chemical Highway 3142, Gate 28- Health Services, Hahnville, LA 70057 | |
(985) 783-4590 | |
Not Available |
Full Name | Dr Dennis Garrett Gruwell |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | Dow Chemical Highway 3142, Hahnville, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1932247715 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 08024R (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Dennis Garrett Gruwell, MD 3 Zee Ann Dr, Luling, LA 70070-3130 Ph: (985) 783-4590 | Dr Dennis Garrett Gruwell, MD Dow Chemical Highway 3142, Gate 28- Health Services, Hahnville, LA 70057 Ph: (985) 783-4590 |
News Archive
By offering all children in Africa vaccines that protect against bacterial infections, researchers say the number of deaths among children living with sickle-cell anemia could be reduced, Reuters reports. An estimated 200,000 children in Africa annually are born with sickle-cell anemia, a genetic disease "in which red blood cells deform into a sickle shape and cluster, blocking blood flow and causing pain, vulnerability to infections and organ damage."
Human problems rarely occur in a vacuum, but persist as part of ongoing social interaction in which causes and effects are interwoven.
Mastectomy has historically been the standard treatment for breast cancer patients experiencing recurrence after an initial lumpectomy and whole-breast radiation. Now, a phase 2 clinical trial led by Douglas W. Arthur, M.D., chair and professor in the Department of Radiation Oncology at VCU Massey Cancer Center and VCU School of Medicine, has demonstrated an effective alternative.
Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden accurately identifies non-small cell lung cancer (NSCLC) patients who could benefit from immunotherapies called checkpoint inhibitors.
› Verified 5 days ago